Datametrex Provides Update On Health Canada Submission & Welcomes Advisors
April 21 2020 - 4:00AM
Datametrex AI Limited (the
“
Company” or “
Datametrex”)
(
TSXV: DM, FSE: D4G, OTC: DTMXF )
wishes to provide additional specifics on the previously announced
news release regarding acquiring the rights to import COVID-19 test
kits from South Korea. An application for approval was made to
Health Canada under the Fast-Track program on April 9th, 2020.
As part of the submission, the Company has
submitted a Medical Devices Interim Order Request Form under
Interim Order Respecting the Importation and Sale of Medical
Devices for Use in Relation to COVID-19 pursuant to subsection
30.1(1) of the Food and Drugs Act signed by the Minister of Health
on March 18, 2020. This Interim Order (IO) will allow Health Canada
to issue expedited review and approval for the sale of these test
kits in Canada.
The Company has represented to Health Canada
that it will be able to provide a minimum first order of 200,000
units, followed by an additional 100,000 units on a weekly basis.
Any purchase of the test kits by the Canadian government is
conditional on prior receipt of Health Canada approval. Datametrex
is currently working with Dr. Lisa Palleson-Stallan and Dr. Joseph
Curtis to assist with obtaining Health Canada approval, and each
has agreed to join the Company’s advisory board.
Dr. Joseph Curtis is the Chief Scientific
Officer and founder of BioQuant Laboratories (BQL) an independent
testing laboratory providing analytical testing services to firms
across the U.S. and Canada developing natural product medicines for
human and animal health. Dr. Curtis has twenty-five years of
experience across and has held various executive positions within
public and private sector firms. Working across the public health
emergency medical countermeasures continuum, he supported the USA’s
blood and tissue preparedness and response programs managed by the
American Red Cross. In this capacity, he served as the Director,
Biomedical Headquarters Facility Quality Assurance coordinating
performance excellence programs across a nation-wide network of
manufacturing and testing facilities delivering $2 billion of
cellular therapies and transfusion medicine products to over 3,000
hospitals across the US.
Dr. Lisa Palleson-Stallan obtained her Ph.D in
International Business with Honours in the U.K. She ran a European
Union funded project on technology and Innovation and completed
post doctoral work at the World Health Organization (WHO)
publishing on Tobacco Cessation. She created her first retail
company, Lotuswear, which grew into a 100 employee + company and
had the role as presidentand CEO. She became an early adopter in
several industries and has continued building value from the ground
up. She has built a successful consultancy company that targets the
Asian marketplace within the Health space. Dr Palleson-Stallan has
been given role and title of Global Health Advisor to assist the
Chinese Government with unconditional support and authority to
conduct negotiations regarding how to best to combat the spread of
Covid-19.
“We are thrilled to be in a position to bring
high quality test kits to Canada to help flatten the curve and save
lives. We are doing everything we can to provide Health Canada with
the required information to move forward. We are looking forward to
solving these problems alongside Dr. Palleson-Stallan and Dr.
Curtis.”, says Marshall Gunter, CEO of the Company.
Datametrex anticipates that it will have little
or no upfront costs associated with importing these test kits.
Assuming Health Canada approves the test kits and they are
subsequently purchased by the Canadian government, manufacturer
will ship the test kits directly to the Canadian government or
hospitals, and Datametrex will not be involved in the shipping,
warehousing or distribution process.
About Datametrex AI Limited
Datametrex AI Limited is a technology-focused
company with exposure to Artificial Intelligence and Machine
Learning through its wholly-owned subsidiary, Nexalogy
(www.nexalogy.com).Additional information on Datametrex is
available at www.datametrex.com
For further information, please
contact:
Marshall Gunter – CEOPhone: (514) 295-2300Email:
mgunter@datametrex.com
Jeff Stevens – Co-FounderPhone: (647)
400-8494Email: jstevens@datametrex.com
Neither the TSX Venture Exchange nor it's
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains "forward-looking
information" within the meaning of applicable securities laws. All
statements contained herein that are not clearly historical in
nature may constitute forward-looking information. In some cases,
forward-looking information can be identified by words or phrases
such as "may", "will", "expect", "likely", "should", "would",
"plan", "anticipate", "intend", "potential", "proposed",
"estimate", "believe" or the negative of these terms, or other
similar words, expressions and grammatical variations thereof, or
statements that certain events or conditions "may" or "will"
happen, or by discussions of strategy.
Readers are cautioned to consider these and
other factors, uncertainties and potential events carefully and not
to put undue reliance on forward-looking information. The
forward-looking information contained herein is made as of the date
of this press release and is based on the beliefs, estimates,
expectations, and opinions of management on the date such
forward-looking information is made. The Company undertakes no
obligation to update or revise any forward-looking information,
whether as a result of new information, estimates or opinions,
future events or results or otherwise or to explain any material
difference between subsequent actual events and such
forward-looking information, except as required by applicable
law.
DataMetrex AI (TSXV:DM)
Historical Stock Chart
From Sep 2024 to Oct 2024
DataMetrex AI (TSXV:DM)
Historical Stock Chart
From Oct 2023 to Oct 2024